![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 22, 19697-19702, May 31, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the a Department of Life Science, College of
Natural Science, Daejin University, Kyeonggido 487-711, Korea,
b Department of Immunology, College of Medicine, Keimyung
University, Taegu 700-712, Korea, c Department of
Physiology, College of Medicine, The Catholic University of Korea,
Seoul 137-701, Korea, d Department of Biochemistry, College
of Medicine, Yeungnam University, Taegu 705-717, Korea,
e Department of Biological Science, College of Natural
Science, Myongji University, Kyeonggido 449-728, Korea,
f Mitsubishi Kasei Institute of Life Sciences, Machida-shi,
Tokyo 194, Japan, g Institute of Biological Science,
University of Tsukuba, Ibaraki 305-8572, Japan, h In2Gen,
Cancer Research Institute, Seoul National University, College of
Medicine, Seoul 110-799, Korea, and i Department of Life
Science, Pohang University of Science and Technology,
Kyungbuk 790-784, Korea
Received for publication, November 26, 2001, and in revised form, February 7, 2002
The pleckstrin homology (PH) domain is a small
motif for membrane targeting in the signaling molecules. Phospholipase
C (PLC)- Regulation of phosphoinositide metabolism by
PLC- For protein-protein interactions, PLC- The PH domain is a 120-amino acid residue stretch that has been
identified in over 100 proteins (9-12). The PH domain binds with high
specificity and affinity to phosphoinositides including PIP,
PIP2, and IP3 (13-15). The PH domain of
signaling molecules is involved in targeted translocation of molecules
to cell membranes (13, 16, 17). Also, the PH domain mediates
protein-protein interaction as well as protein-lipid interaction
including the PLC- Since the first step of PIP2 biosynthesis is the
phosphorylation of PI by PI-4 kinase to produce PI-4-P, which is
phosphorylated by PI-4-P-5 kinase (PI-4-P kinase) to produce
PIP2, it is probably true that EF-1 Reagents--
Anti-EF-1 In Vitro Binding Assay Using GST Fusion Protein--
All the GST
fusion proteins were engineered by PCR using rat EF-1 Determination of the Partial Amino Acid
Sequence--
GST·PH-bound proteins were separated by 10% SDS-PAGE
and stained with Coomassie Brilliant Blue R-250. The prominent band was excised and digested with lysylendopeptidase AP-1 for 14 h, and the resulting peptides were separated by reverse-phase high pressure liquid chromatography C8 column chromatography as described
previously (35). Amino acids from the NH2 terminus
of the peptides were analyzed by a pulse-liquid phase protein sequencer
(PE-Biosystems, model 492 cLC).
PLC- Far Western Blot Analysis--
Purified EF-1 Dot-blot Analysis--
The ability of the proteins to bind
different phospholipids was examined using Dot-blot analysis (39).
Briefly, chloroform-solubilized phospholipids (3 µg of each) were
spotted onto nitrocellulose membrane (PROTRAN, Schleicher & Schuell),
and then the membrane was dried at room temperature for 1 h. The
following steps are exactly the same method as for Far Western
blotting. The membrane was blocked with 2% non-fat skim milk in TBT
buffer for 1 h. The membranes were then incubated with purified
EF-1 A Split PH Domain of PLC- nPH2 Domain of PLC- PIP2 Potentiates the Binding Affinity of PH Domain to
EF-1 EF-1 Many reports have described the activation mechanisms and
functional roles of PLC- We showed that an NH2-terminal split PH domain of PLC- The addition of PIP2, a PLC- The activation of PLC- EF-1 In vivo, the complex of PLC- We thank Dr. Takuji Shirasawa (Tokyo
Metropolitan Institute of Gerontology) for providing rat EF-1 *
This work was supported by Grant 2000-015-DP0317 from the
Korea Research Foundation (to J.-S. C.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
j
To whom correspondence should be addressed. Tel.:
82-31-539-1853; Fax: 82-31-539-1850; E-mail:
jchang@road.daejin.ac.kr.
Published, JBC Papers in Press, March 8, 2002, DOI 10.1074/jbc.M111206200
2
C. J.-S. Chang, H. Seok, T.-K. Kwon,
D. S. Min, B.-H. Ahn, Y. H. Lee, J.-W. Suh, J.-W. Kim, S. Iwashita,
A. Omori, S. Ichinose, O. Numata, J.-K. Seo, Y.-S. Oh, and P.-G. Suh,
unpublished data.
The abbreviations used are:
PLC, phospholipase C;
EF, elongation factor;
PH, pleckstrin homology;
PI, phosphatidylinositol;
PIP, phosphatidylinositol 4-phosphate;
PIP2, phosphatidylinositol 4, 5-bisphosphate;
PIP3, phosphatidylinositol 3,4,5-trisphosphate;
GST, glutathione S-transferase;
HRP, horseradish peroxidase;
PE, phosphatidylethanolamine;
IP3, inositol
1,4,5-trisphosphate;
SH, Src homology;
TBT, Tris-buffered Tween 20;
n, NH2-terminal portion;
c, COOH-terminal portion;
t, T. pyriformis.
Interaction of Elongation Factor-1
and Pleckstrin Homology
Domain of Phospholipase C-
1 with Activating Its Activity*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 has two putative PH domains, an
NH2-terminal and a split PH domain. Here we report
studies on the interaction of the PH domain of PLC-
1 with
translational elongation factor (EF)-1
, which has been shown
to be a phosphatidylinositol 4-kinase activator. By pull-down of cell
extract with the glutathione S-transferase (GST) fusion
proteins with various domains of PLC-
1 followed by peptide sequence
analysis, we identified EF-1
as a binding partner of a split PH
domain of PLC-
1. Analysis by site-directed mutagenesis of the PH
domain revealed that the
2-sheet of a split PH domain is critical
for the interaction with EF-1
. Moreover, Dot-blot assay shows that a
split PH domain specifically binds to phosphoinositides including
phosphatidylinositol 4-phosphate and phosphatidylinositol 4, 5-bisphosphate (PIP2). So the PH domain of PLC-
1 binds
to both EF-1
and PIP2. The binding affinity of EF-1
to the GST·PH domain fusion protein increased in the presence of
PIP2, although PIP2 does not bind to EF-1
directly. This suggests that EF-1
may control the binding affinity
between the PH domain and PIP2. PLC-
1 is substantially
activated in the presence of EF-1
with a bell-shaped curve in
relation to the molar ratio between them, whereas a double point mutant
PLC-
1 (Y509A/F510A) that lost its binding affinity to EF-1
shows
basal level activity. Taken together, our data show that EF-1
plays
a direct role in phosphoinositide metabolism of cellular signaling
by regulating PLC-
1 activity via a split PH domain.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
11 is important
for cell proliferation, differentiation, and migration. Many extracellular signals stimulate the hydrolysis of PIP2 by
the activation of PLC-
1, which produces inositol
1,4,5-trisphosphate (IP3) and diacylglycerol. Both second
messengers regulate the release of Ca2+ from intracellular
stores and activate protein kinase C, respectively (1, 2). On the roles
of PLC-
1 in cell growth and differentiation, recent findings
demonstrate that overexpression of PLC-
1 induces malignant
transformation in nude mice (3), and targeted deletion of PLC-
1
results in embryonic lethality in mice (4).
1 has two Src homology
(SH) 2 domains to bind to tyrosine-phosphorylated proteins including several growth factor receptors (5-8). Although a large variety of
proteins are identified as interacting counterparts of the SH2-SH2-SH3
domain of PLC-
1, the activation mechanism of PLC-
1 remains obscure.

-subunit of heteromeric G-protein (18, 19), protein
kinase C (20), actin (21), and BAP-135 (22). By analyzing the tertiary structure, the PH domain is an antiparallel
-sheet consisting of
seven strands (23, 24).
1 has two putative PH domains: one is located in the
amino-terminal 150-amino acid residue, and the other is split by the
SH2-SH2-SH3 domain (see Fig. 1A). Upon growth factor
stimulation, the NH2-terminal PH domain of PLC-
1 is
targeted to the plasma membrane and binds to phosphatidylinositol
3,4,5-trisphosphate (PIP3) but not to PIP2
(25). In an effort to identify the PH domain ligands and to understand
the phosphoinositide regulation mechanism of PLC-
1, we used the
GST·PH fusion protein system. We found that a split half of the PH
domain of PLC-
1 directly binds to EF-1
, which is known for PI-4
kinase activating protein in plants (26, 27).
, as a PI-4 kinase
activator, has a pivotal role in regulating phospholipid metabolism.
There is, however, no report on the roles of EF-1
as a PI-4 kinase
activator in mammalian cells, so our present data are the first
demonstration of the roles of eukaryotic EF-1
in mammalian
phosphoinositide metabolism. In addition to the involvement of protein
translation (28, 29), EF-1
is involved in cytoskeletal rearrangement
(30). Furthermore, overexpression of EF-1
correlates with metastasis
(31) and leads to increased susceptibility to oncogenic transformation (32). Here we describe that EF-1
directly binds to the PH domain to
activate PLC-
1.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
monoclonal antibody and horseradish
peroxidase (HRP)-conjugated goat anti-mouse antibody were purchased
from Upstate Biotechnology Inc. (Lake Placid, NY). Anti-GST antibody
and HRP-conjugated donkey anti-goat antibody were from Amersham
Biosciences and Jackson ImmunoResearch Laboratories (West Grove, PA),
respectively. All the phospholipids including
phosphatidylethanolamine (PE), PIP, and PIP2 were from
Sigma. Lysylendopeptidase AP-1 was obtained from Wako Pure Chemical
(Osaka, Japan).
cDNA (33) and rat PLC-
1 cDNA (34) as templates. Briefly, PCR
was carried out between a 5' primer with a EcoRI recognition site and a 3' primer with a XhoI recognition site at the 5'
extension, corresponding to the individual PH domains, respectively.
PCR products were ligated into the pGEX-5X-1 vector (Amersham
Biosciences). Point mutant PH domains of PLC-
1 were also engineered
by PCR. All of the DNA constructs were confirmed by DNA sequencing.
Expression and purification of fusion proteins using
glutathione-Sepharose 4B (Amersham Biosciences) were performed per the
manufacturer's specifications. GST fusion proteins used in this study
were as follows: GST·PH1 (coding residue amino acids
25-145 of PLC-
1), GST·nPH2 (amino acids 477-547 of
PLC-
1), GST·cPH2 (amino acids 850-979 of PLC-
1),
GST·PHGAP (amino acids 461-612 of p120 kDa rasGTPase activating
protein), GST·SH2n (amino acids 550-667 of PLC-
1), GST·SH2c
(amino acids 668-735 of PLC-
1), GST·SH3 (amino acids 791-836 of
PLC-
1), and GST·EF-1
(whole amino acid sequence of rat
EF-1
). Proteins bound to GST fusion proteins were washed extensively with Nonidet P-40 buffer (20 mM Tris-Cl,
pH 7.5, 1% Nonidet P-40, 300 mM NaCl, 2 mM
MgCl2, 1 mM EDTA, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate), resolved in 10% SDS-PAGE, and
then transferred to polyvinylidene difluoride membranes (Bio-Rad). The
membrane-bound proteins were detected with the ECL detection system
using anti-EF-1
monoclonal antibody and HRP-conjugated goat
anti-mouse antibody.
1 Activity Assay--
PLC-
1 activity was measured as
described previously (36). Briefly, substrate was prepared as sonicated
vesicles of 75 mM [3H]PIP2
(9,000-10,000 cpm/assay, PerkinElmer Life Sciences) and 750 mM PE in 50 mM HEPES buffer (pH 7.0) containing
2 mM CaCl2. Reactions were performed for 20 min
at 30 °C in a 60-µl final volume and terminated by the
addition of 1 ml of chloroform/methanol/HCl (50:50:0.3) and 0.45 ml of
1 N HCl. The mixtures were vortexed and centrifuged for 10 min at 2,000 rpm. The aqueous phase containing [3H]IP3 was collected and subjected to a
scintillation counter. The effect of EF-1
was examined by adding the
indicated amount of EF-1
to the PLC-
1 assay mixture.
Tetrahymena pyriformis EF-1
was homogeneously purified by
the method described before (37). Wild type PLC-
1 and its mutant
form (Y509A/F510A) were homogeneously prepared as described previously
(38).
(0.2 µg/lane)
was resolved in 10% SDS-PAGE and transferred onto a polyvinylidene
difluoride membrane. Nonspecific binding to the membrane was blocked by
adding 2% skim milk in Tris-buffered Tween 20 (TBT) for 1 h at
room temperature. The membranes were then incubated with GST,
GST·nPH2, or GST·nPH2·Y509A/F510A mutant proteins (0.5 µg/ml) in blocking buffer for 14 h at
4 °C. After washes in TBT buffer, the membranes were incubated with anti-GST antibody for 2 h at room temperature. After washing the membrane with TBT buffer, bound proteins were detected by successive incubation with HRP-conjugated anti-goat antibody as a second antibody
using the ECL detection system.
, GST, GST·EF-1
, GST·nPH2, GST·mutant
(Y509A/F510A) nPH2 proteins (0.5 µg/ml), respectively, in
blocking buffer for 14 h at 4 °C. After washes with TBT buffer,
the membranes were incubated with anti-EF-1
monoclonal antibody and
anti-GST antibody for 2 h at room temperature, respectively. After
washing the membrane again with TBT buffer extensively, bound proteins
were detected by successive incubation with HRP-conjugated anti-mouse
for EF-1
and anti-goat antibody as second antibody for GST fusion
proteins using the ECL detection system, respectively.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 Directly Binds to
EF-1
--
PLC-
1 has two putative PH domains in the molecule. To
search for proteins that specifically bind to the PH domains of
PLC-
1, we prepared three kinds of GST·PH domain fusion proteins in
Escherichia coli (GST·PH1,
GST·nPH2, and GST·cPH2). These purified
GST·PH fusion proteins were incubated with lysate of NIH 3T3 cells,
respectively (Fig. 1, A and
B). Among them, GST·nPH2 fusion proteins
specifically pulled down a prominent protein with a molecular size of
48 kDa. To identify the protein, the band was cut from the gel and
subjected to a protein sequencer after lysylendopeptidase digestion. We obtained two peptide sequences, P1 and P2. P1 is YYVTIIDAPGHRDFIK, and
P2 is TGHLIYK. When these sequences were searched by the NCBI data base
of SWISS-PLOT, they were found to match 58 species of EF-1
sequence
reported. P1 and P2 correspond to the 105-120th and 24-30th amino
acids of human EF-1
, respectively. Then we confirmed the band with
48 kDa as EF-1
with Western immunoblotting using anti-EF-1
monoclonal antibody (Fig. 1C). To further clarify the
binding region of PLC-
1 to EF-1
, we examined binding capacity using several other GST fusion proteins including
GST·PH1, GST·cPH2, GST·SH2, GST·SH3,
GST·PH·GAP, and PH·GAP. As shown in Fig. 1C, only GST·nPH2 associates with EF-1
, as judged by
Western immunoblotting. We next tested whether the binding is direct or
not; Far Western blotting using purified protozoan T. pyriformis EF-1
(tEF-1
) was used for this. Since EF-1
is
highly conserved and has very similar biochemical properties among
different species in eukaryotes (28), we used tEF-1
due to
its success with purification steps with high purity (37). The result
of Far Western blotting clearly showed a direct binding between
GST·nPH2 and tEF-1
(Fig.
2, A and B).
Moreover, a double point mutation in GST·nPH2 fusion
protein (Y509A/F510A) lost its binding affinity to tEF-1
(Fig.
3, A and B). To
confirm the interaction between the PH domain and EF-1
in
vivo, immunoprecipitation was carried out to detect a
PLC-
1·EF-1
complex in COS-7 cells. The immunoprecipitates of
EF-1
isolated by anti-EF-1
antibody included PLC-
1, detected
by Western immunoblot by anti-PLC-
1 antibody or vice versa (Fig.
2C). Also, the yeast two-hybrid assay was introduced to show
in vivo interaction between EF-1
and the nPH2
domain of PLC-
1 (Fig. 2D). The mutant nPH2 domain did not bind to EF-1
in either yeast two-hybrid assay. These
results clearly demonstrate that the nPH2 domain of
PLC-
1 directly binds to EF-1
.

View larger version (27K):
[in a new window]
Fig. 1.
Isolation of EF-1
as
a split PH domain of PLC-
1 binding
protein. A, PLC-
1 has two putative PH domains
(PH1 and split PH2) in addition to the SH2n,
SH2c, SH3, and catalytic X and Y domains. A split PH domain consists of
NH2-terminal portion (nPH2) and COOH-terminal
portion (cPH2). B, three GST fusion proteins of
GST·PH1, GST·nPH2, and
GST·cPH2 incubated with (+) or without (
) NIH 3T3 cell
lysates. The bound proteins were isolated by pull-down and subjected to
10% SDS-PAGE. A prominent protein with 48 kDa (indicated by an
open arrowhead) was detected from GST·nPH2
fusion protein followed by Coomassie Brilliant Blue staining.
C, various GST fusion proteins incubated with NIH 3T3 cell
lysates. The bound proteins were resolved on 10% SDS-PAGE followed by
immunoblotting using anti-EF-1
monoclonal antibody. WCL
indicates the whole cell lysates used for each pull-down
experiment.

View larger version (19K):
[in a new window]
Fig. 2.
nPH2 domain of
PLC-
1 directly binds to
EF-1
. A,
GST·nPH2 fusion protein was incubated with
purified Tetrahymena EF-1
(tEF-1
) in Nonidet P-40
buffer containing 1% bovine serum albumin. The bound tEF-1
was
subjected to immunoblotting with anti-EF-1
antibody. B,
purified tEF-1
(0.2 µg/lane) was subjected to 10% SDS-PAGE. The
protein was then transferred to a nylon membrane and probed with either
anti-EF-1
antibody (left, Western blot) or purified GST,
GST·nPH2 and GST·nPH2·Y509A/F510A
proteins (right, Far Western blot), respectively. Left
panel, the filter was probed with HRP-conjugated goat anti-mouse
antibody. Right panel, the filter was incubated with
anti-GST antibody followed by HRP-conjugated donkey anti-goat antibody.
C, immunoprecipitation (IP) analysis. COS-7 cell
lysate was immunoprecipitated using anti-EF-1
antibody and
anti-PLC-
1 antibody (F-7), and the immunoprecipitates were subjected
to immunoblotting with anti-PLC-
1 antibody (upper) or
anti-EF-1
antibody (lower). WCL, the whole
cell lysates used for each pull-down experiment. D,
yeast two-hybrid assay. cDNAs from GST·nPH2
and GST·nPH2·Y509A/F510A, respectively, were inserted
into the EcoRI/XhoI site of the pGilda LexA
vector (CLONTECH). A full-length EF-1
cDNA was inserted into the
EcoRI/XhoI site of the pB42AD (activation domain)
vector (CLONTECH). The yeast two-hybrid assay was
carried out according to the manufacturer's specifications.

View larger version (23K):
[in a new window]
Fig. 3.
Mapping of the EF-1
binding site within the nPH2 domain of
PLC-
1. A, schematic
representation of the elements of the secondary structure. Amino acid
sequences of the nPH2 domain (corresponding to the
-sheets 1-3) of PLC-
1 are depicted with the single-letter codes.
Positions of the mutated amino acids are shown under the
wild type amino acids. B, in vitro binding assay
with various mutant GST·nPH2 fusion proteins. NIH 3T3
cell lysates (300 µg) were incubated with 2-5 µg each of various
mutant GST fusion proteins immobilized onto glutathione-Sepharose
beads. Bound proteins were separated on SDS-PAGE and transferred to a
polyvinylidene difluoride membrane. Bound EF-1
was detected by
immunoblotting using anti-EF-1
antibody. WCL, the whole
cell lysates used for each pull-down experiment.
2-Sheet of nPH2 Domain Is Critical for Binding to
EF-1
--
Fine mapping of the EF-1
binding site was carried out
within the nPH2 domain of PLC-
1. Since aromatic residue
has a potential for protein-protein interaction via hydrophobic
interaction, we substituted aromatic residues including tyrosine and
phenylalanine for alanine within the
2- and
3-sheet (Fig.
3A). Several mutants of the nPH2 domain induced
by site-directed mutagenesis were expressed as GST fusion proteins,
mixed with lysates of NIH 3T3 cells, pulled down, and subjected to
immunoblotting with anti-EF-1
antibody. The results demonstrate that
amino acid residues Tyr-509 and Phe-510 of the
2-sheet play critical
roles in the interaction between EF-1
and the PH
domain of PLC-
1 (Fig. 3B). A double point mutant Y509A/F510A completely abolishes the interaction, and another double
point mutant Y506A/P507A of the
2-sheet of PLC-
1 also shows
reduced binding affinity to EF-1
. However, the truncated mutant
GST·tnPH2 (amino acids 495-547) that lacks a portion of the
1-sheet has an equal binding capacity to that of
nPH2 (amino acids 477-547) (data not shown). These results
indicate that the association between EF-1
and the nPH2
domain of PLC-
1 is due to hydrophobic interaction via the
2-sheet
of PLC-
1.
1 Specifically Binds to PIP and
PIP2--
To explore the binding region of PLC-
1 to
phosphoinositides, we used GST·nPH2, mutant
GST·nPH2·Y509A/F510A, GST·EF-1
, and GST proteins
for dot-blotting (lipid-protein blotting). Different lipids (each 3 µg) including PE, PIP, and PIP2 were spotted onto nitrocellulose membrane, and the membrane was blotted as described under "Experimental Procedures." As shown in Fig.
4, a double point mutant of
GST·nPH2·Y509A/F510A without binding affinity for EF-1
binds to PIP and PIP2 with a similar
capacity as wild type GST·nPH2, whereas GST·EF-1
and
GST as a control do not show any binding capacity to phospholipids.
Also, purified tEF-1
did not show any binding affinity to
phospholipids (data not shown). These results suggest that the
nPH2 domain of PLC-
1 has different binding sites for
EF-1
and phospholipid. It is noteworthy that the nPH2
region serves as a substrate PIP2-binding site, whereas the
NH2-terminal PH domain (PH1) of PLC-
1 has
been reported to interact with PIP3 for
membrane-targeted translocation (25).

View larger version (63K):
[in a new window]
Fig. 4.
Dot-blot assay of GST·fusion proteins with
phospholipids. Each chloroform-solubilized phospholipid (3 µg)
was spotted on nitrocellulose membrane for Dot-blot assay. The filter
was incubated with 0.5 µg/ml GST or GST fusion proteins for 14 h
at 4 °C. The phospholipid-bound proteins were detected by the ECL
detection system as described under "Experimental
Procedures."
--
Since both substrate PIP2 and EF-1
bind to the nPH2 domain of PLC-
1, we investigated
whether they compete with each other for binding to the PH domain.
However, we found that the association between the nPH2
domain of PLC-
1 and EF-1
significantly increased in the presence
of PIP2 but not in either PE or PIP up to its concentration
of 100 µg/ml phospholipid (Fig. 5).
Complex formation of GST·nPH2·EF-1
increased in a
PIP2 dose-dependent manner.

View larger version (49K):
[in a new window]
Fig. 5.
PIP2 increases binding activity
of GST·nPH2 domain to EF-1
.
A, GST·nPH2 (4 µg)-coupled beads incubated
with NIH 3T3 cell lysate in the presence of 0, 10, 50, or 100 µg/ml
sonicated phospholipid vesicles. Each resulting bead was divided into
two equal portions for measuring the bound EF-1
(upper)
and for normalization by amounts of GST·nPH2 proteins
(lower), respectively. Both proteins were accessed by
immunoblotting with anti-EF-1
antibody or by anti-GST antibody
followed by the second antibody. B, amounts of bound EF-1
expressed by relative image density (Quantity One, Bio-Rad), which was
normalized by GST·nPH2. The experiments were carried out
three times with similar results.
Activates PLC-
1 Activity--
To examine whether the
complex formation of both proteins affects PLC-
1 enzymatic activity,
we measured its catalytic activity. Since we confirmed that tEF-1
specifically associates with PLC-
1 (Fig. 2, A and
B), we used tEF-1
for its effect on PLC-
1 activity. After preincubation of the purified tEF-1
with either PLC-
1 or
mutant PLC-
1 (Y509A/F510A) at 4 °C for 1 h,
[3H]PIP2 hydrolyzing activity was measured.
As shown in Fig. 6, EF-1
activates
wild type PLC-
1 activity in a bell-shaped manner, whereas
mutant PLC-
1 (Y509A/F510A) shows basal level activity even in the
presence of EF-1
. The activity of wild type PLC-
1 is accelerated
about 3-fold under the condition of 1:2 molar ratio (PLC-
1 to
EF-1
).

View larger version (24K):
[in a new window]
Fig. 6.
Modulation of PLC-
1
activity in the presence of EF-1
.
PIP2 hydrolyzing activity of PLC-
1 and its Y509A/F510A
mutant form was measured in an assay mixture containing various amounts
of EF-1
as indicated by the molar ratio to PLC-
1. PLC-
1
activity is expressed as the radioactivity of amounts of
[3H]IP3. Data represent the average of
duplicate determination (mean ± range) from one of the two
experiments with similar results.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 in cellular signaling. Generally, growth factor stimulation leads to the binding of the SH2 domains of PLC-
1
to the autophosphorylated receptor, and then PLC-
1 is subsequently
activated by tyrosine phosphorylation of Tyr-783 followed by
PIP2 hydrolysis to IP3 and diacylglycerol.
However, the degree of tyrosine phosphorylation of PLC-
1 does not
correlate well with its enzyme activity. For example, some ligands
strongly stimulate tyrosine phosphorylation of PLC-
1 with low
IP3 production (6), and some ligands highly induce the
production of IP3 with weak tyrosine phosphorylation of
PLC-
1 (7). There might be alternative controlling mechanism(s) of
PLC-
1 activity in cellular signaling. To identify a responsible
molecule(s) for regulation of PLC-
1, we have searched for binding
proteins to PLC-
1 and found EF-1
, a PI-4 kinase activator.
1
specifically binds to EF-1
and that PIP2, a substrate of
PLC-
1, increases its association with EF-1
. It is noteworthy that
the strict region of PLC-
1 plays a role for protein-protein
interaction other than the SH2 and SH3 domains in PLC-
1. Although
extensive studies on the role of the PH domains were done in PLC-
(17), -
(41, 42), and -
1 (25) and PI-4 kinase (39), those of a
split PH domain of PLC-
1 had not been examined. By pull-down experiments with GST·nPH2 using a detergent lysate of NIH
3T3 cells, EF-1
was identified by peptide sequence analysis. The association between the nPH2 domain and EF-1
is highly
specific. Since EF-1
has been reported to be an activating protein
of PI-4 kinase (26, 27), it is meaningful that the association might play a critical role for PLC-
1 in cellular signaling.
1 substrate, to the
incubation mixture of the GST·nPH2 domain fusion protein
and cell extracts containing EF-1
, the complex formation of
GST·nPH2·EF-1
, was dramatically increased in a
PIP2 concentration-dependent manner. On this point,
it is interesting that the stable complex between PLC-
1 and its
substrate PIP2 was detected by Dot-blot analysis (Fig. 4).
Therefore, we can speculate that the PH domain of PLC-
1 associates
with PIP2 first, and the PH domain/PIP2
complex formation induces the conformational change to allow EF-1
to
bind PLC-
1. EF-1
binding to PLC-
1 might facilitate the
hydrolysis of PIP2 by PLC-
1. In this context, the role
of PLC-
1-bound EF-1
is a possible regulator for PIP2 hydrolysis.
1 activity by EF-1
showed a bell-shaped
curve (Fig. 6). The maximum activity was at around a 1:2 molar ratio,
whereas the activity decreased to basal level at higher than 1:8 molar
ratios. There might be several reasons to explain the bell-shaped
curve. One is that EF-1
has a very basic isoelectric point and is
easily aggregated at high density (43, 44). Another possibility is that
component(s) such as Ca2+/CaM molecules are contaminated in
EF-1
preparation. Although the preparation of tEF-1
is highly
pure, the contamination of Ca2+/CaM molecules or other
components could not be completely excluded. Generally, EF-1
preparation contains Ca2+/CaM molecules to some
extent (40, 45). In this regard, Ca2+/CaM might sequester
Ca2+ supplements for maximal PLC-
1 activity at high
doses of EF-1
addition.
promotes the production of PIP and PIP2 by the
activation of PI-4 kinase, and eventually this newly produced
PIP2 hydrolysis is also accelerated by EF-1
via PLC-
1
activation. EF-1
activates both PI-4 kinase (26, 27) and
PLC-
1, which can bind to PIP and PIP2. However, they
regulate the level of PIP and PIP2 in a different manner.
The former regulates the level of PIP and PIP2 by
phosphorylation of PI at the D-4 position of the inositol ring, whereas
the latter regulates the phospholipid level by hydrolyzing PIP2 to IP3 and diacylglycerol. Therefore,
EF-1
has the potential to induce a rapid PI turnover in a cell.
1·EF-1
was detected by
immunoprecipitation not only from quiescent cells but also from
epidermal growth factor- or platelet-derived growth factor-stimulated
cells, and so far no significant difference was observed between them. However, using green fluorescent protein fusion proteins, serum, and lysophosphatidic acid increased their complex formation around the
cell membrane.2 Although we
need more detailed analysis for the PLC-
1 activation mechanism, our
results show a direct interaction between PLC-
1 and EF-1
that
elucidates the phospholipid metabolisms induced by PLC-
1 in cellular signaling.
![]()
ACKNOWLEDGEMENT
cDNA.
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Berridge, M. J.
(1993)
Nature
361,
315-325[CrossRef][Medline]
[Order article via Infotrieve]
2.
Nishizuka, Y.
(1995)
FASEB J.
9,
484-496[Abstract]
3.
Chang, J.-S.,
Noh, D. Y.,
Park, I. A.,
Kim, M. J.,
Song, H.,
Ryu, S. H.,
and Suh, P.-G.
(1997)
Cancer Res.
57,
5465-5468 4.
Ji, Q.-S.,
Winnier, G. E.,
Niswender, K. D.,
Horstman, D.,
Wisdom, R.,
Magnuson, M. A.,
and Carpenter, G.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2999-3003 5.
Cockcroft, S.,
and Thomas, G. M.
(1992)
Biochem. J.
288,
1-14[Medline]
[Order article via Infotrieve]
6.
Kim, H. K.,
Kim, J. W.,
Zilberstein, A.,
Margolis, G.,
Kim, C. K.,
Schlessinger, J.,
and Rhee, S. G.
(1991)
Cell
65,
435-441[CrossRef][Medline]
[Order article via Infotrieve]
7.
Rhee, S. G.,
and Bae, Y. S.
(1997)
J. Biol. Chem.
272,
15045-15048 8.
Rhee, S. G.
(2001)
Annu. Rev. Biochem.
70,
281-312[CrossRef][Medline]
[Order article via Infotrieve]
9.
Haslam, R. J.,
Koide, H. B.,
and Hemmings, B. A.
(1993)
Nature
363,
309-310[Medline]
[Order article via Infotrieve]
10.
Mayer, B. J.,
Ren, R.,
Clark, K. L.,
and Baltimore, D.
(1993)
Cell
73,
629-630[CrossRef][Medline]
[Order article via Infotrieve]
11.
Gibson, T. J.,
Hyvonen, M.,
Musacchio, A.,
Saraste, M.,
and Birney, E.
(1994)
Trends Biochem. Sci.
19,
349-353[CrossRef][Medline]
[Order article via Infotrieve]
12.
Lemmon, M. A.,
and Ferguson, K. M.
(2000)
Biochem. J.
350,
1-18[CrossRef][Medline]
[Order article via Infotrieve]
13.
Lemmon, M. A.,
Falasca, M.,
Ferguson, K. M.,
and Schlessinger, J.
(1997)
Trends Cell Biol.
7,
237-242[Medline]
[Order article via Infotrieve]
14.
Rebecchi, M. J.,
and Scarlata, S.
(1998)
Annu. Rev. Biophys. Biomol. Struct.
27,
503-528[CrossRef][Medline]
[Order article via Infotrieve]
15.
Lemmon, M. A.,
and Ferguson, K. M.
(1998)
Curr. Top. Microbiol. Immunol.
228,
39-74[Medline]
[Order article via Infotrieve]
16.
Lemmon, M. A.,
Ferguson, K. M.,
and Schlessinger, J.
(1996)
Cell
85,
621-624[CrossRef][Medline]
[Order article via Infotrieve]
17.
Razzini, G.,
Brancaccio, A.,
Lemmon, M. A.,
Guarnier, S.,
and Falasca, M.
(2000)
J. Biol. Chem.
275,
14873-14881 18.
Touhara, K.,
Inglese, J.,
Pitcher, J. A.,
Shaw, G.,
and Lefkowitz, R. J.
(1994)
J. Biol. Chem.
269,
10217-10220 19.
Pitcher, J. A.,
Touhara, K.,
Payne, E. S.,
and Lefkowitz, R. J.
(1995)
J. Biol. Chem.
270,
11707-11710 20.
Yao, L.,
Suzuki, H.,
Ozawa, K.,
Deng, J.,
Lehe, C.,
Fukamachi, H.,
Anderson, W. G.,
Kawakami, Y.,
and Kawakami, T.
(1997)
J. Biol. Chem.
272,
13033-13039 21.
Yao, L.,
Janmey, P.,
Friger, L. G.,
Han, W.,
Fujita, J.,
Kawakami, Y.,
Apgar, J. R.,
and Kawakami, T.
(1999)
J. Biol. Chem.
274,
19752-19761 22.
Yang, W.,
and Desiderio, S.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
604-609 23.
Yoon, H. S.,
Hajduck, P. J.,
Petros, A. M.,
Olejniczak, E. T.,
Meadows, R. P.,
and Fesik, S. W.
(1994)
Nature
369,
672-675[CrossRef][Medline]
[Order article via Infotrieve]
24.
Macias, M. J.,
Musacchio, A.,
Ponstingl, H.,
Nilges, M.,
Saraste, M.,
and Oschikinat, H.
(1994)
Nature
369,
675-677[CrossRef][Medline]
[Order article via Infotrieve]
25.
Falasca, M.,
Logan, S. K.,
Lehto, V. P.,
Baccante, G.,
Lemmon, M. A.,
and Schlessinger, J.
(1998)
EMBO J.
17,
414-422[CrossRef][Medline]
[Order article via Infotrieve]
26.
Yang, W.,
Burkhart, W.,
Cavallius, J.,
Merrick, W. C.,
and Boss, W. F.
(1993)
J. Biol. Chem.
268,
392-398 27.
Yang, W.,
and Boss, W. F.
(1994)
J. Biol. Chem.
269,
3852-3857 28.
Riis, B.,
Rattan, S. I. S.,
Clark, B. F. C.,
and Merrick, W. C.
(1990)
Trends Biochem. Sci.
15,
420-424[CrossRef][Medline]
[Order article via Infotrieve]
29.
Negrutskii, B. S.,
and Elskaya, A. V.
(1998)
Prog. Nucleic Acid Res. Mol. Biol.
60,
47-78[Medline]
[Order article via Infotrieve]
30.
Condeelis, J.
(1995)
Trends Biochem. Sci.
20,
169-170[CrossRef][Medline]
[Order article via Infotrieve]
31.
Taniguchi, S.,
Miyamoto, S.,
Sadano, H.,
and Kobayashi, H.
(1992)
Nucleic Acids Res.
19,
6949
32.
Tatsuka, M.,
Mitsui, H.,
Wada, M.,
Nagata, A.,
Nojima, H.,
and Okayama, H.
(1992)
Nature
359,
333-336[CrossRef][Medline]
[Order article via Infotrieve]
33.
Shirasawa, T.,
Sakamoto, K.,
Akashi, T.,
Takahashi, H.,
and Kawashima, A.
(1992)
Nucleic Acids Res.
20,
909 34.
Suh, P.-G.,
Ryu, S. H.,
Moon, K. H.,
Suh, H. W.,
and Rhee, S. G.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
5419-5423 35.
Nishiki, T.,
Kamata, Y.,
Nemoto, Y.,
Omori, A.,
Ito, T.,
Takahashi, M.,
and Kozaki, S.
(1994)
J. Biol. Chem.
269,
10498-10503 36.
Hepler, J. R.,
Kozasa, T.,
Smrcka, A. V.,
Simon, M. I.,
Rhee, S. G.,
Sternweis, P. C.,
and Gilman, A. G.
(1993)
J. Biol. Chem.
268,
14367-14375 37.
Takeda, T.,
Kurasawa, Y.,
Watanabe, Y.,
and Numata, O.
(1995)
J. Biochem. (Tokyo)
117,
869-874 38.
Bae, S. S.,
Perry, D. K., Oh, Y.-S.,
Choi, J. H.,
Galadari, S. H.,
Ghayur, T.,
Ryu, S. H.,
and Suh, P.-G.
(2000)
FASEB J.
14,
1083-1092 39.
Stevenson, J. M.,
Perera, I. Y.,
and Boss, W. F.
(1998)
J. Biol. Chem.
273,
22761-22767 40.
Kaur, K. J.,
and Ruben, L.
(1994)
J. Biol. Chem.
269,
23045-23050 41.
Kavran, J. M.,
Klein, D. E.,
Lee, A.,
Falasca, M.,
Isakoff, S. J.,
Skolnik, E. Y.,
and Lemmon, M. A.
(1998)
J. Biol. Chem.
273,
30497-30508 42.
Yagisawa, H.,
Sakuma, K.,
Paterson, H. F.,
Cheung, R.,
Allen, V.,
Hirata, H.,
Watanabe, Y.,
Hirata, M.,
Williams, R.,
and Katan, M.
(1998)
J. Biol. Chem.
273,
417-424 43.
Edmonds, B. T.,
Bell, A.,
Wyckoff, J.,
Condeelis, J.,
and Leyh, T. S.
(1998)
J. Biol. Chem.
273,
10288-10295 44.
Carvalho, M.,
Carvalho, J.,
and Merrick, W.
(1984)
Arch. Biochem. Biophys.
234,
603-611[CrossRef][Medline]
[Order article via Infotrieve]
45.
Numata, O.,
Kurasawa, Y.,
Gonda, K.,
and Watanabe, Y.
(2000)
J. Biochem. (Tokyo)
127,
51-56
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
T. M. Leclercq, P. A. B. Moretti, M. A. Vadas, and S. M. Pitson Eukaryotic Elongation Factor 1A Interacts with Sphingosine Kinase and Directly Enhances Its Catalytic Activity J. Biol. Chem., April 11, 2008; 283(15): 9606 - 9614. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-K. Heo, M.-A Yoon, S.-C. Lee, S.-A Ju, J.-H. Choi, P.-G. Suh, B. S. Kwon, and B.-S. Kim HVEM Signaling in Monocytes Is Mediated by Intracellular Calcium Mobilization J. Immunol., November 1, 2007; 179(9): 6305 - 6310. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. DeBell, L. Graham, I. Reischl, C. Serrano, E. Bonvini, and B. Rellahan Intramolecular Regulation of Phospholipase C-{gamma}1 by Its C-Terminal Src Homology 2 Domain Mol. Cell. Biol., February 1, 2007; 27(3): 854 - 863. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wen, J. Yan, and M. Zhang Structural Characterization of the Split Pleckstrin Homology Domain in Phospholipase C-{gamma}1 and Its Interaction with TRPC3 J. Biol. Chem., April 28, 2006; 281(17): 12060 - 12068. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Piechulek, T. Rehlen, C. Walliser, P. Vatter, B. Moepps, and P. Gierschik Isozyme-specific Stimulation of Phospholipase C-{gamma}2 by Rac GTPases J. Biol. Chem., November 25, 2005; 280(47): 38923 - 38931. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Chang, S.-K. Kim, T.-K. Kwon, S. S. Bae, D. S. Min, Y. H. Lee, S.-O. Kim, J.-K. Seo, J. H. Choi, and P.-G. Suh Pleckstrin Homology Domains of Phospholipase C-{gamma}1 Directly Interact with {beta}-Tubulin for Activation of Phospholipase C-{gamma}1 and Reciprocal Modulation of {beta}-Tubulin Function in Microtubule Assembly J. Biol. Chem., February 25, 2005; 280(8): 6897 - 6905. [Abstract] [Full Text] [PDF] |
||||
![]() |